MAC regimen

MAC regimen

Gynecologic oncology A regimen for managing choriocarcinoma Agents MTX, dactinomycin, chlorambucil; MR 'failures' may respond to other chemotherapy–eg, bleomycin, cisplatin, hydroxyurea, vinblastine
Mentioned in ?
References in periodicals archive ?
Notably, a single-center study of 52 patients with T-cell lymphoma showed that RIC regimens had a seven-fold increased risk of relapse compared with MAC regimens.[22] In general, antilymphoma activity of RIC regimens is weaker than MAC regimens, and RIC is associated with a higher risk of relapse and lower TRM.
MAC regimens were increasingly used in patients with PTCLs recently.
Based on these controversial literature data regarding the comparison of RIC vs myeloablative conditioning (MAC) in patients with ALL, one may conclude that further prospective trials and head to head comparisons are needed in order to evaluate efficacy of RIC or MAC regimens in ALL.